Evommune Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Evommune, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023
Period EndingDec 2024Dec 2023
Revenue & Gross Profit
Revenue7.005.00
Cost of Revenue1.290.00
Gross Profit7.005.00
Operating Expenses
Research & Development64.2432.00
Selling, General & Administrative12.7710.85
Operating Expenses77.0142.85
Operating Income-70.01-37.85
Other Income/Expense
Interest Income3.243.86
Interest Expense-0.03-0.06
Other Income/Expense0.000.00
Income
Income Before Tax-66.81-34.05
Income Tax Expense0.000.00
Net Income-66.81-34.05
Net Income - Continuous Operations-66.810.00
Net Income - Discontinued Operations0.000.00
EBITDA-68.73-36.85
EBIT-70.01-37.85
Depreciation & Amortization1.291.00
Earnings Per Share
Basic EPS-45.00-27.00
Diluted EPS-45.00-27.00
Basic Shares Outstanding1.511.25
Diluted Shares Outstanding1.511.25